ICR cancer drug NXP800 to enter Phase I trials
An investigational drug called NXP800, discovered at the Cancer Research UK Cancer Therapeutics Unit at London’s Institute of Cancer Research (ICR), is to enter Phas...
Insights into the latest developments in CDMO services and manufacturing.
Continue readingExpert perspectives on the evolving needs of injectable therapies and packaging.
Continue readingExploring the latest developments in inhalation technologies, respiratory delivery and sustainability
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement